DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
— - 2 Alex Fuhrman - 2 Oprah Winfrey - 1 Oprah giveth - 1 Oprah taketh - 1 maven - 1 Winfrey - 1 — WeightWatchers - 1
Top related locs:
GLP WeightWatchers New York City U.S Herbalife University of North Carolina
Top related orgs:
CNBC - 2 WW International - 1 Service - 1 SEC - 1 Guardian - 1 People Magazine - 1 MarketWatch - 1 Mayo Clinic - 1

Search resuls for: "Alex Fuhrman"


4 mentions found


☆ Oprah has left WeightWatchers, sending stocks spiraling and spelling doom for the diet of our foremothers
  + stars: | 2024-02-29 | by ( Mia De Graaf | Rachel Hosie | ) www.businessinsider.com   time to read: +7 min
Oprah Winfrey will not seek reelection to the board of WW International, known as WeightWatchers. It was a surprising time to jump on board — WeightWatchers had been shedding users, and its stock price was dwindling. AdvertisementDespite not naming the brand, there was an immediate spike in demand for GLP-1 medications — the popular new class of weight-loss drugs. That same day, WW added a weight-loss drug arm to its business, acquiring Sequence, a service that provides weight-loss drugs. AdvertisementLong-term, WW needs to find a new identityOver time, WW will benefit from being a purveyor of hard-to-access weight-loss drugs.
Persons: Oprah Winfrey, —, Oprah giveth, Oprah taketh, maven, Winfrey, — WeightWatchers, Axios, Oprah, Forbes, Craig, Alex Fuhrman, Winfrey's, We're, Atkins Organizations: WW International, Service, SEC, Guardian, People Magazine, MarketWatch, Mayo Clinic, Business, Smithsonian's National Museum of, CNBC, Slate Locations: GLP, WeightWatchers
☆ Thinking about taking new weight loss drugs? These are the big health risk decisions that will follow
  + stars: | 2024-02-28 | by ( Eric Rosenbaum | ) www.cnbc.com   time to read: +6 min
In this article NOVO.B-DKLLYWWGWW Follow your favorite stocks CREATE FREE ACCOUNTAn injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. But will Americans trust the most iconic brand in the legacy weight-loss business to guide them into its future? "Big pharma was coming for weight loss, and if they didn't have a clinical angle, they would have run the risk of becoming an irrelevant company." "This is a new, incredibly powerful and effective class of pharmaceuticals that a lot of people will find help improve their health." watch nowRisks of overreliance on obesity drugs The risk is real that providers may use the medications and "forget about lifestyle," said John Batsis, an associate professor and nutrition expert at the University of North Carolina Chapel Hill's school of public health.
Persons: Eli Lilly’s, Brendan Mcdermid, Eli Lilly, —, Sima Sistani —, Sistani, Alex Fuhrman, Hallum, Fuhrman, Davidson, Linda Bolton Weiser, I've, Geoff Cook, Cook, John Batsis, Batsis Organizations: Reuters, Novo Nordisk, CNBC, Craig, pharma, University of North, University of North Carolina Chapel Locations: New York City, U.S, Herbalife, University of North Carolina
☆ Small caps will be large this year, says Jefferies. Here are 10 buy ideas
  + stars: | 2023-04-20 | by ( Alex Harring | ) www.cnbc.com   time to read: +3 min
Small-cap stocks could beat their large-cap counterparts in 2023, according to Jefferies. Equity strategist Steven DeSanctis said small-cap stocks have cheap relative valuations while volume has slid, high-yield spreads have tightened and cyclicals have been sold off. Expectations are low with poor sentiment for small caps, DeSanctis said. Taken together with the attractive valuations, improving merger and acquisition landscape and better macroenvironment, he said he believes small caps will outperform in 2023. Given this varied landscape, DeSanctis screened for smaller-cap stocks that have lagged year to date but do well in Jefferies' modeling.
☆ Under threat, Weight Watchers enters obesity drug space. Here's what it means for the stock
  + stars: | 2023-03-07 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +7 min
The company's sales have been in a steady multiyear decline after an attempt to de-emphasize weight loss and focus on wellness failed miserably. WW 1Y mountain The parent of Weight Watchers has seen its market value shrink as sales have dropped for several years. Another drug, Eli Lilly's Mounjaro, adds a second incretin hormone to the mix and has been shown to be even more successful with weight loss. This trend could provide an opportunity for the core Weight Watchers brand and its focus on behavior modification. That scenario assumes Weight Watchers continues to see membership erosion, while cost controls help minimize margin compression.
0 next >>
Total: 4